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Abstract 
The Ebola virus Viral Protein 24 (VP24) inhibits interferon signaling through its interaction with the human 
protein Karyopherin, thus impairing the immune response of the host against the infection and increasing its 
rate of diffusion into the organism and its lethality. This makes of VP24 a potential pharmacological target, 
as the inhibition of its interaction with Karyopherin could reduce Ebola virus virulence. In this work, we 
carried out an atomic level study of the network of interactions between VP24 and Karyopherin using 
molecular dynamics and computational alanine scanning. Modeling the VP24-Karyopherin complex allowed 
us to identify the amino acid residues responsible for protein-protein binding and led to the identification of 
a nonapeptide with VP24 binding potential. Subsequently, the ability of this peptide to actually bind VP24 in 
solution has been assayed by Saturation Transfer Difference NMR and Circular Dichroism (CD). Experimental 
and molecular modeling data concerning the VP24-peptide complex have been compared and putative 
peptide binding site and mode are discussed.  
 
 
 
 
 
  Introduction 
Ebola virus (EBOV) epidemics have repeatedly burst in equatorial Africa in the last decades, highlighting the 
need of new therapies against this disease. EBOV virus belongs to the Filoviridae family of single stranded, 
non-segmented negative-sense RNA viruses. EBOV is the etiologic agent of a haemorrhagic fever with a very 
high human fatality rate, ranging from 50% to near 90%.1 The virulence and high lethality of this virus are due 
to diverse factors, in particular to its ability to inhibit both the innate immune response in the early stages of 
infection and the subsequent adaptive specific immune responses of the host organism.2,3 This is done by 
different strategies, in particular by the suppression of interferon (IFN)-α/β production and inhibition of 
interferon-induced antiviral activity.4,5 Ebola's genome codes for seven proteins, so there is a very limited 
number of viral targets available. Moreover, only one of them, the viral large (L) RNA-dependent RNA 
polymerase protein, has an enzymatic activity, while all the remaining EBOV proteins exert their function 
through protein–protein interactions, among themselves or with human proteins. This makes protein-
protein interactions targeting a necessary strategy for contrasting EBOV infection. Recently, different 
research groups focused their attention on Viral Protein 35, a multitasking and attractive target in the Ebola 
proteome6-8. In this work, we consider Viral Protein 24 (VP24), which acts as an inhibitor of interferon (IFN) 
signaling, as a potential target. Immune response of the organism to a viral infection is due to interferons, 
through the phosphorylation of the STAT (signal transducer and activator of transcription) protein operated 
by the Janus kinase9. The phosphorylated STAT is recognized by a subset of Karyopherin α (KPNA) family of 
nuclear transport factor. This STAT-KPNA complex is transported in the cell nucleus where it induces the 
expression of ISG gene, that has an antiviral activity.10,11 VP24 acts in a cell intrinsic manner inhibiting IFN 
signaling and making cells refractory to IFN as it forms a complex with KPNA, thus making it unavailable for 
the STAT transportation into the cell nucleus.12 Inhibition of VP24-Karyopherin interaction is a possible 
therapeutic strategy to reduce Ebola virulence. Targeting protein-protein interactions (PPIs) is a difficult task, 
due to the inherent features of protein-protein contact surfaces, which are often flat and lack well defined 
pockets, and to their variability13,14. Nevertheless, in recent years many encouraging results have been 
obtained, showing that exploiting PPIs as therapeutic targets is a viable, albeit challenging option15,16, and 
several PPIs targeting molecules, both of peptidic17-19 and non peptidic nature20-22, have been described. 
Among the molecular modeling techniques aimed  to study PPIs, computational alanine scanning23 (CAS) is a 
widely used one. It consists in the evaluation of the difference in the binding free energy of the proteins 
forming a complex upon mutation of each of the interfacial residues into alanine. This evaluation is 
performed with a posteriori free energy calculation approaches, such as the MM/PBSA24, on snapshots 
extracted from a molecular dynamics trajectory. This kind of approach has been successfully used to identify 
peptides acting as PPIs inhibitors and corresponding to protein subsets located at the protein-protein 
interface25-27, as well as to describe the interactions between protein surface and small molecule binders28,29. 
Among the experimental techniques suitable for studying transient protein-peptide complexes the Nuclear 
Magnetic Resonance spectroscopy (NMR) is one of the most powerful and versatile method, well suited to 
provide a detailed description of the receptor-ligand interactions30,31. In particular Saturation Transfer 
Difference (STD-NMR) technique is one of the most widespread NMR methods to study the interactions 
between small ligands and macromolecular receptors32. In this work we performed an atomic level mapping 
of the interactions between VP24 and Karyopherin, employing molecular dynamics simulations in explicit 
solvent and free energy calculations, and identified a small subset of residues at the VP24-KPNA interface 
responsible for protein complex formation. In particular, such critical residues belonging to Karyopherin were 
used as the basis for the design of a nine residues long peptide potentially able to interact with VP24, thus 
competitively inhibiting its interaction with Karyopherin. To evaluate whether the identified peptide could 
retain its ability to interact with VP24 even when extracted from its protein environment, molecular dynamics 
simulation of the peptide-VP24 complex were performed, as well as CAS, in order to evaluate the structural 
and energetic behavior of the peptide. The interaction between VP24 and the identified peptide was then 
experimentally investigated through circular dichroism (CD) and advanced NMR techniques. The interactions 
between the Ebola receptor and the nonapeptide ligand are governed by weak forces including Van der 
Waals interactions, hydrogen bonding and hydrophobic associations. In this case, the ligand-based NMR 
approach represent an optimal angle of observation, because it permits the analysis of interactions governed 
by weak equilibrium dissociation constants (in the micromolar to the millimolar range), focusing on the 
ligand33. We confirmed the binding of the peptide with VP24 protein and mapped the interaction epitope by 
determining the ligand regions in contact with the receptor.  
 
Materials and Methods 
Molecular dynamics 
The crystallographic structure of the complex VP24-KPNA was obtained from the Protein Data Bank (PDB 
code: 4U2X12), and the residue numbering used here is referred to such structure. Molecular dynamics 
simulations were carried out with the GROMACS 4.5.334 package using explicit solvent and periodic boundary 
conditions. The AMBER99SB-ildn35 force field was used. Every system was solvated with TIP4P36 waters and 
neutralized with Cl- or Na+ ions to reach neutrality. The LINCS algorithm37 was employed to constraint all 
bonds to their equilibrium length, allowing a time step of 2 fs. The system was submitted to 10’000 steps of 
geometry optimization with the steepest descent method. Afterwards it was equilibrated for 200 ps in NVT 
conditions (T=300 K) and subsequently for 200 ps in NPT conditions, in order to equilibrate systems density. 
For the VP24-KPNA complex a 50 ns molecular dynamics was performed in NPT conditions (1 bar, T=300 K). 
For each of the peptide-VP24 complexes, a 100 ns molecular dynamics was run in the aforementioned 
conditions. Temperature and pressure were kept constant to their reference value using the velocity rescale 
algorithm38 and the Berendsen barostat39, respectively. A 14 Å cutoff was applied for non-bonded 
interactions and the Particles Mesh Ewald algorithm40 was employed to calculate long range electrostatic 
interactions. 
Computational alanine scanning 
500 snapshots were extracted from the last 20 ns of the dynamics of the VP24-K complex (one snapshot 
every 40 ps). Solvent accessible surface area (SASA) of each residue was calculated using Naccess41. The ΔG 
of binding was calculated with the MM/PBSA approach as implemented in the GMXPBSA 2.0 suite42-45. This 
protocol implicitly assumes that point mutations in the protein do not significantly affect its conformation. 
The validity of this assumption in computational alanine scanning has been widely confirmed in the literature, 
when applied to protein-protein interactions46-47. A dielectric constant of 2 was chosen for protein interior.  
The same protocol was employed for the computational alanine scanning for each VP24-peptide complex. 
VP24 purification  
The portion of Ebola virus VP24 protein comprising residues 1-233 and lacking the structurally disordered 18-
residue C-terminal region was produced in Escherichia coli strain Rosetta(DE3) fused to an N-terminal poly-
His sequence to facilitate its purification, using the plasmid construct based on pET-46 EkLIC vector described 
elsewhere48,49. Bacterial cultures grown under agitation in 2×YT medium, supplemented with 30 mg/L 
chloramphenicol and 100 mg/L ampicillin, were induced with 0.2 mM isopropil--D-1-tiogalattopiranoside 
for 16 h at 25 °C. Cells (typically 15 g wet weight) were suspended in 30 mL of 50 mM Na-phosphate, pH 7.4, 
containing 200 mMNaCl, 5 mM imidazole (Solution A), added with Complete® EDTA-free protease inhibitor 
cocktail (Sigma-Aldrich), and disrupted by sonication. After removal of cell debris by centrifugation, the crude 
extract was loaded on two 5 mL HisTrap HP cartridges (GE Healthcare) connected in series, equilibrated with 
Solution A. After extensive washing, initially with Solution A and then bringing imidazole concentration to 25 
mM, VP24 elution was obtained by a 25-500 mM imidazole concentration gradient over 80 mL in Solution A. 
After protein concentration by ultrafiltration to about 25 mg/mL, solvent was changed to 50 mM Na-
phosphate, 500 mM NaCl by gel filtration on a HiTrap desalting column (GE Healthcare). Purified VP24 
(typically 80 mg) was subdivided into aliquots and stored at -20 °C. The extinction coefficient used to 
quantitate recombinant VP24 was determined by measuring its absorbance at 280 nm in 50 mM Na-
phosphate, pH 7.4, 200 mM NaCl, in the absence and in the presence of 5 M guanidine hydrochloride. Then, 
from the 280 value computed through the ExPASy server for the protein under denaturing conditions50 a 280 
of 31,390 M-1cm-1 for native VP24 1-233 fragment was obtained.  
 
Peptide synthesis  
The peptide RS (AYGLDKIEF) was prepared by microwave-assisted solid phase synthesis51 based on Fmoc 
chemistry on Fmoc-Rinkamide resin (0.57 meq/g substitution), using a fivefold molar excess of 0.2 M Fmoc-
protected amino acids dissolved in N-methyl pyrrolidinone, and using HOBT/HBTU/DIEA (5 : 5 : 10 eq) as 
activators. Coupling reactions were performed for 5 min at 40 W with a maximum temperature of 75 °C. 
Deprotection was performed in two stages using 20% piperidine in dimethylformamide (5 and 10 min each). 
The peptide was acetylated using Ac2O (10 eq) and DIEA (10 eq) in DCM/DMF (1:3). The coupling reaction 
was performed twice for 0.5 h each time. Cleavage from the resin was performed using 10 mL of Reagent K 
(trifluoroacetic acid/phenol/water/thioanisole/ 1,2-ethanedithiol; 82.5 : 5 : 5 : 5 : 2.5) for 180 min. Following 
cleavage, the peptide was precipitated and washed using ice-cold anhydrous ethyl ether. The peptide was 
purified by RP-HPLC using a gradient elution of 5–70% solvent B (solvent A: water/acetonitrile/trifluoroacetic 
acid 95 : 5 : 0.1; solvent B: water/acetonitrile/trifluoroacetic acid 5 : 95 : 0.1) over 20 min at a flow rate of 20 
mL/min. The purified peptide was freeze-dried and stored at 0 °C. 
Circular Dichroism 
CD spectra were collected using a Jasco J-810 spectropolarimeter. Peptide RS stock solution was prepared in 
50 mM PBS (100 µM, pH 7.4). VP24 stock solution was prepared in 50 mM PBS and 200 mM NaCl (95 µM, pH 
7.4). Spectra were obtained from 200 to 260 nm with a 0.1 nm step and 1 s collection time per step, taking 
three averages. The spectrum of the buffer was subtracted to eliminate interference from cell, solvent, and 
optical equipment. The CD spectra were plotted as mean residue ellipticity (degree x cm2 x dmol-1) versus 
wave length (nm). Noise-reduction was obtained using a Fourier-transform filter program from Jasco. 
Nuclear Magnetic Resonance 
The peptide was characterized by one- and two-dimensional NMR experiments. NMR spectra were collected 
on samples containing 2 mM peptide in 20 nM phosphate buffer (containing 10% D2O). The assignment52 are 
reported in the Table S2 of Supplementary Information. The spectra were acquired with a Bruker Avance 500 
MHz instrument at 298 K. TOCSY spectra, with a mixing time of 60 ms, allow reaching a complete assignment 
of all the spin systems of the amino acids. NOESY experiments with mixing times of 700 ms and ROESY with 
mixing time of 200 ms were used to evaluate the spatial correlations. In 1D, TOCSY, NOESY and ROESY 
experiments, solvent suppression was achieved using the excitation sculpting pulse sequence. In STD 
experiments 5000 Hz (10 ppm) and -100 Hz (-0.2 ppm) were used as on-resonance irradiation, while 100000 
Hz (200 ppm) was chosen as off-resonance. A train of Gauss shaped pulses of 49 ms length each achieved a 
selective pre-saturation of the protein. The experiments were performed with 2.94 s of total saturation. In 
the STD experiment water suppression was achieved by use of the WATERGATE 3–9–19 pulse sequence. STD 
experiment was acquired also in absence of protein in order to exclude artifacts. In the analysis of the binding, 
the final concentrations of peptide and protein were about 1.1 mM and 22 M, respectively, resulting in a 
50:1 ligand-target ratio.  
Results and Discussion 
Computational alanine scanning 
A molecular dynamics of 50 ns was performed on the VP24-KPNA complex. Computational alanine scanning 
(CAS) was carried out in the last 20 ns of the dynamics when the system was fully equilibrated as shown by 
RMSD plot (Fig. S1-S2). In general, a few nanoseconds long trajectories allow a sufficient sampling for an 
accurate binding free energy calculation with the MM/PBSA approach and consequently for CAS purposes53. 
The protein-protein interface is defined as the ensemble of amino acids whose solvent exposed surface area 
has a nonzero variation upon complex formation and it is composed of 56 residues. Residues whose mutation 
led to a variation in binding free energy (ΔΔG) greater than 2 kcal mol-1 are defined as hot-spots. CAS results 
are summarized in Table 1. Hot spots are evenly distributed between VP24 and KPNA, which contain 10 and 
11 hot spots respectively (Fig.1a).  
 
Fig. 1 A) VP24 (blue)-KPNA (cyan) complex.  The hot-spots arising from the CAS analysis are highlighted in 
orange. B) The hydrophobic cluster at the VP24-KPNA interface. C) Overview of the five salt bridges at the 
VP24-K interface. D) VP24 (blue) in complex with the RS peptide (cyan) extracted from KPNA. Figures were 
rendered with VMD58. 
The two proteins exhibit a high degree of electrostatic complementarity, as can be inferred from electrostatic 
potential maps (Fig. S3-S4). A more detailed insight into the network of interactions at the interface that 
contribute to VP24-KPNA complex formation can be achieved by the analysis of the local environment of the 
hot spots during the simulation. As we can see from Table 1, since most of the hot-spots are either charged 
or polar residues, most of the interactions within the VP24-KPNA complex are salt bridges and hydrogen 
bonds, although hydrophobic hot spots and non-polar interactions are also observed. In particular, Arg140 
and Glu475’ (residues belonging to KPNA are labeled with a prime on their sequence number) form a salt 
bridge that is populated along 88% of the MD trajectory, while salt bridges between Glu203 and Lys 399’, 
between Asp205 and Arg396’ and between Asp124 and Lys481’ are populated during 85%, 78% and 64% of 
the trajectory respectively (Fig.1c). Residue Asp124 is also involved in a hydrogen bond between its carboxyl 
group and Thr434’ hydroxyl, which is observed during 75% of the simulation, while Arg137 and Asp480’ 
backbones form a hydrogen bond for 74% of the trajectory. A small hydrophobic cluster, comprising Leu121, 
Val141 and Tyr477’, Phe484’ and the aliphatic portion of the sidechain of Lys481’ has been also observed and 
is steadily formed during the whole simulation (Fig. 1b). An interaction table for the complex VP24-KPNA can 
be found in supplementary material (Table S3). Table 1 also shows the presence of some residues exhibiting 
a largely negative ΔΔG (i.e. residues whose mutation into alanine increase the binding energy between the 
proteins). These are Glu88, Glu394’, Asp431’ and Asp437’. Inspecting the electrostatic potential on VP24 and 
KPNA surface, it may be observed (Fig. S5-S6) that all these negatively charged residues, when the complex 
is formed, actually face a negative potential area on the binding partner. This suggest a somehow suboptimal 
affinity of VP24 for KPNA, which deserves further attention and should be investigated by molecular 
biologists. Stemming from these geometric and energetic features of the VP24-KPNA interface, we identified 
two KPNA segments comprising a set of hot spot residues that are close to one another not only in the protein 
tridimensional structure, but also in its sequence. The binding capability of an isolated peptide is not 
guaranteed in principle, even if it contains several hot spots, because it may undergo major structural 
rearrangements when isolated from the parent protein and because of the complexity of the interaction 
networks that lead to protein complex formation. The first sequence we considered, comprising the hot spot 
residues Arg396’, Arg398’ and Lys399’, ranges from Ala393’ to  Glu400’. A 100ns MD simulation of this 
peptide in complex with VP24 shows large conformational changes (Fig. S12), leading to a partial detachment 
of the peptide from the protein. In particular, the salt bridge interactions involving the former hot-spots are 
completely lost. For these reasons the peptide seems unable to interact with VP24, thus it was no longer 
considered. The second sequence comprises residues ranging from Glu474’ to Phe484’. A 100ns MD 
simulation and a CAS of the peptide-VP24 complex were performed in order to evaluate the binding 
capability of the selected sequence. Both Glu474’ (hot spot in VP24-KPNA complex) and Glu475’ lost their 
hot spot character showing negative ΔΔG  values (Fig. S11),   while all the remaining hot spots are conserved. 
Based on these results we decided to shorten the sequence discarding Glu474’ and Glu475’, obtaining a less 
charged peptide maintaining a very high density of hot spots, namely Tyr477’, Asp480’, Lys481’ and Phe484’. 
We inferred that a peptide sequence corresponding to this KPNA subsequence could bind to VP24, thus 
interfering with VP24-KPNA complex formation. The selected peptide (from now on named RS, Fig. 1d) 
involves residues ranging from Ala476’ to Phe484’ and has the sequence AYGLDKIEF. To investigate whether 
the identified peptide could retain its ability to bind to VP24, even when extracted from its protein 
environment, we ran a 100 ns long control molecular dynamics simulations of the VP24–RS complex. The 
protein-peptide complex showed a good structural stability during the whole simulation, with protein binding 
site and peptide binding mode well conserved. On the other hand, its helical secondary structure was 
progressively relaxed and eventually lost during the simulation (Fig. S7). 
 
Tab.1 Computational Alanine Scanning data with standard errors. Left column refers to VP24 residues, right 
column to KPNA residues. Hot spots are reported in bold. 
 
Mutation ∆∆𝐺 / 𝑘𝑐𝑎𝑙 𝑚𝑜𝑙−1 𝑒𝑟𝑟 / 𝑘𝑐𝑎𝑙 𝑚𝑜𝑙−1  Mutation ∆∆𝐺 / 𝑘𝑐𝑎𝑙 𝑚𝑜𝑙−1 𝑒𝑟𝑟 / 𝑘𝑐𝑎𝑙 𝑚𝑜𝑙−1 
GLU88 -10.99 0.79  LEU390 0.10 0.79 
GLU113 6.16 0.79  GLN391 0.41 0.79 
LEU121 6.28 0.79  GLU394 -13.16 0.79 
ASP124 4.35 0.79  PHE395 1.43 0.76 
TRP125 0.96 0.79  ARG396 21.04 0.79 
LEU127 0.14 0.79  ARG398 18.80 0.74 
THR128 -0.64 0.79  LYS399 23.07 0.84 
THR129 1.53 0.79  LYS427 16.67 0.79 
ASN130 0.24 0.79  ASP431 -14.81 0.79 
THR131 -0.21 0.79  LEU433 0.50 0.79 
PHE134 1.84 0.79  THR434 6.09 0.79 
ASN135 3.30 0.79  VAL435 1.19 0.79 
MET136 1.62 0.79  MET436 3.63 0.79 
ARG137 23.84 0.81  ASP437 -13.57 0.74 
THR138 -2.89 0.79  GLU474 7.91 0.79 
GLN139 0.29 0.79  GLU475 1.98 0.79 
ARG140 9.94 0.79  TYR477 6.31 0.79 
VAL141 2.65 0.79  LEU479 0.62 0.79 
GLN184 -1.55 0.79  ASP480 17.56 0.79 
ASN185 1.15 0.74  LYS481 28.90 0.81 
HIS186 0.14 0.79  GLU483 0.79 0.79 
LEU201 1.27 0.79  PHE484 6.02 0.79 
GLN202 -0.07 0.79  LEU485 0.55 0.79 
GLU203 10.37 0.72  SER487 -1.53 0.79 
ASP205 16.31 0.76  HIS488 1.15 0.79 
SER207 0.24 0.79  GLU489 -4.44 0.76 
ASN210 -0.38 0.79  ILE501 -0.45 0.79 
LYS218 11.13 0.79  PHE505 1.00 0.79 
Subsequently, a CAS was carried out in order to verify if the previously identified KPNA hot spots were 
conserved also in the VP24-RS complex. As shown in Fig. 2 and Table S1, not only all the hot spots are 
conserved, but also a new one, i.e. Glu483’, can be identified. This residue forms a salt bridge with Arg137 
which is observed in 90% of the trajectory of the VP24-RS complex. Interestingly, this salt bridge, albeit 
present also in the VP24-KPNA complex, was observed only in 31% of the trajectory.  
 
Fig. 2 Computational Alanine Scanning results for residues ranging from Tyr 477’ to Phe 484’ belonging to 
Karyopherin (blue bars) or to the RS peptide (red bars). 
 
Nuclear Magnetic Resonance 
In order to experimentally verify if RS can actually bind VP24 in solution, NMR experiments were performed. 
First, the capped-peptide was analyzed in terms of conformational features by NOESY (500ms) and ROESY 
(200ms), observing no medium and long-range correlations. Only sequential correlations could be found, 
indicating that the peptide exists in random conformation. tr-NOESY and tr-ROESY experiments showed no 
definite secondary structure in the peptide even upon addition of VP24. These observations mirror the 
behavior of RS in MD simulations, both alone and in complex with VP24 (Fig. S8-S9). In this paper, STD 
technique was used as an epitope mapping device to describe the VP24-peptide interactions. The method is 
based on the transfer of saturation from the protein to the bound peptide which in turn, by exchange, is 
moved into solution where it is detected. During the period of saturation, the magnetization gradually moves 
from the protein to the protons of the peptide when the ligand binds to the target. For transient interactions 
with rapid exchange54,55, the ligand polarization in the bound state is transferred to the free state where the 
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saturation accumulates during the irradiation time of the experiment. The STD spectrum shows only the 
signals of peptide that were in close contact with the protein (Fig. 3). 
 
Fig. 3. Up) selected regions of1H-NMR spectrum of 1.1 mM peptide in the presence of 22 M VP24 protein in 
phosphate buffer, resulting in a 50:1 ligand-target ratio. The signal labeled with an asterisk is due to the Lys, 
Leu and Ile amide protons which show the same chemical shift. Bottom) The same region of the STD spectrum.  
 To better assess the interaction strength, the percentage of absolute STD was calculated (Fig. S10, Table S2). 
Figure 4 shows the absolute STD percentage (grouped in two intensity ranges) for protons which forms the 
epitope that reflects the relative proximity of the atoms to the binding site. In fact, the ligand protons nearest 
to the protein are most likely to be saturated to the highest degree, and therefore have the strongest signal 
in the mono-dimensional STD spectrum. In particular, the more strictly interacting moieties are the aromatic 
protons of Tyr 477’ and Phe 484’ (1.5 and 1.6 % absolute STD respectively), the amidic proton of Asp 480’ (2 
% absolute STD) and the C-terminal amide protons (1.6 % absolute STD). Although CAS analysis and STD point 
out different aspect of peptide protein interaction (CAS is focused on the energetic of side chain interactions 
highlighted by their mutation into alanine, while STD supplies information on the proximity of a set of 
hydrogen atoms of the peptides with respect to the protein) we may notice that, by and large, the two 
approaches give mutually compatible and sound results.   
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 Fig. 4. Absolute STD% values, grouped in two intensity ranges, for peptide interacting with VP24 toxins. The 
NH-amides of Leu, Lys and Ile, labeled with an asterisk, show the same chemical shift. 
The key role of the aromatic residues Tyr 477’ and Phe 484’, which take part in hydrophobic interactions with 
VP24, are highlighted both by CAS and by NMR analysis. Moreover, the role of charged residues, in particular 
Lys 481’ and Asp 480’, while somehow overestimated by CAS, as often reported in literature56,57, has been 
observed by STD analysis. In order to perform a negative control, we analyzed the linear octapeptide A 
(LGYGFVNY) in the presence of VP24 protein by STD experiment. The A peptide has six residues in common 
with peptide RS, but despite this the interaction with the protein is not observed as showed in figure 2-B (no 
STD signals). The observation that RS can actually form a complex with VP24 in solution and the overall 
agreement between NMR and computational data, support our initial hypothesis that the selected peptide 
could bind to VP24 and suggest the plausibility of the proposed binding site. 
Circular Dichroism 
As a further confirmation of the interaction between RS and VP 24, far-UV circular dichroism (CD) 
experiments were performed. This technique is, indeed, particularly useful for studying protein folding and 
interactions.59 In 50 mM PBS at pH 7.4, RS peptide lacked to adopt an ordered conformation, as it was almost 
random coil (Fig. 5, red line). In the same condition, VP24 is characterized by two negative bands at 210 and 
225 nm (amide n transition), that are typical of  helix (Fig. 5, black line). On the other hand, the absence 
of a positive band below 200 nm (amide  transition) indicated that VP24 is present in solution as a 
mixture different conformations. VP24/RS interaction was then evaluated. A solution containing a mixture of 
RS and VP24 in 50 mM PBS was incubated at room temperature and then CD spectrum was recorded. A 
comparison between the spectrum of experimental mixture (Fig. 5, blue line) and the arithmetic sum of the 
two separated components (Fig. 5, green line) highlighted that, actually, an interaction occurred. 
Furthermore, the decrease in intensity of the negative Cotton effects at 210 and 225 nm in the experimental 
mixture indicated a loss of the helical content of the protein, upon this interaction. 
 
Fig. 5 CD spectra of VP24 (black line), of peptide RS (red line), and of VP24/RS experimental mixture (blue 
line). The green line is the arithmetic sum of VP24 and RS single spectra.  
Conclusions 
In this work we analyzed at the atomic level the network of interactions responsible for the formation of the 
VP24-KPNA complex. The protein-protein interface has been characterized, identifying the hot spots 
residues, that give a major contribution to binding energy. From this analysis, a nonapeptide ranging from 
Ala 476’ to Phe 484’ and comprising four hot spots close to one another both in the tertiary and primary 
structure ok KPNA has been identified. The ability of the selected peptide to actually interact with VP24 has 
been assayed with Saturation Transfer Difference NMR, which allowed to map the interaction epitope by 
determining the peptide regions in contact with the protein receptor. On the whole, the epitope sketched by 
NMR is consistent with the binding mode proposed by molecular modeling. The interaction between the 
selected RS peptide and VP24 was assessed also by far-UV CD experiments. The VP24 protein is a potential 
target for reducing Ebola virus virulence and lethality, but its structure, lacking well defined pockets and 
grooves is far from being easily druggable. The identification of the RS peptide, which interacts with VP24 
through its surface, can be a useful starting point for further development of VP24 targeting active molecules.   
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